Wisevoter
U.S.

Altay Therapeutics Raised $37 Million for FSHD Drug

The biotech firm secured series A funding to advance an experimental oral drug for an inherited muscular dystrophy.

Updated on Oct. 14, 2026 in Biotech

Bold flat-color editorial illustration of a medical vial silhouette, symbolizing clinical medical research and the advancement of drug development.
Altay Therapeutics raised $37 million in series A funding to advance DX5057, an experimental drug targeting the root cause of muscular dystrophy. AI Illustration. Upload story photo >

Live Poll

Do you trust that pharmaceutical firms prioritize developing effective treatments for rare inherited diseases?

Altay Therapeutics raised $37 million in a series A financing round to support the development of its experimental drug, DX5057. The treatment is designed to block DUX4, the transcription factor responsible for facioscapulohumeral muscular dystrophy (FSHD).

Why it matters

The company intends to use the capital to fund Phase I and Phase II clinical trials for DX5057. As there are currently no approved treatments for FSHD in the United States or elsewhere, this candidate represents a potential breakthrough for patients.

DX5057 acts as a small-molecule inhibitor that functions systemically to block DUX4 expression. By targeting this embryonic transcription factor, the drug aims to reduce protein expression and limit progressive muscle damage.

The players

Altay Therapeutics

This biotechnology company focuses on developing small-molecule inhibitors to treat rare muscular diseases.

Sound Bioventures

This venture capital firm invests in European and American life science companies developing innovative medical therapies.

HealthCap

This Nordic-based venture capital firm specializes in financing healthcare and biotechnology companies across the globe.

Biogen New Ventures

This is the corporate venture capital arm of the global biotechnology company Biogen which focuses on neuroscience therapeutics.

The details

The financing round was co-led by Sound Bioventures and HealthCap, with participation from investors including Biogen New Ventures and Pappas Capital. The drug works by inhibiting the gene expression that leads to the muscle wasting characteristic of the disease.

Timeline

  1. March 2026: Sarepta reported SRP-1001 achieved high muscle concentrations.

  2. June 2026: Novartis reported Phase I/II FORTITUDE study trial results.

  3. October 2026: Altay Therapeutics announced $37 million series A funding.

  4. First quarter of 2027: Altay expects to initiate Phase I clinical development.

The Tech Race

This development follows a trend of increasing interest in therapies for FSHD, mirroring recent milestones like the Novartis FORTITUDE Phase I/II study. As firms move away from legacy symptomatic management, the industry is accelerating toward genetically targeted small-molecule inhibitors.

This funding milestone brings a potential new treatment option one step closer to clinical reality for patients suffering from muscular dystrophy. While patients will not see immediate changes in care, the successful advancement of this drug could eventually provide the first available therapy for their condition.

The takeaway

The surge in investment for FSHD-focused companies highlights a growing clinical focus on addressing the genetic roots of muscular dystrophy. Patients should follow the progress of these early-stage trials to understand when potential new treatments might reach the clinical pipeline.

What happens next

Altay Therapeutics is scheduled to begin a Phase I safety study for its FSHD drug DX5057 during the first quarter of 2027.

Further reading

Learn more about the latest industry developments at Biotech.

Source note: This article includes information reported by Firstwordpharma.

Live Poll

Do you trust that pharmaceutical firms prioritize developing effective treatments for rare inherited diseases?